metformin has been researched along with Injury, Myocardial Reperfusion in 37 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study tested the hypothesis that pretreatment with metformin decreases postprocedural myocardial injury and improves clinical outcomes in metabolic syndrome patients following percutaneous coronary intervention (PCI)." | 9.19 | Protective effect of metformin on myocardial injury in metabolic syndrome patients following percutaneous coronary intervention. ( Li, J; Song, SJ; Sun, XJ; Xu, JP; Xu, ZW; Zhao, XZ, 2014) |
| "Metformin is a widely used drug in the treatment of type 2 diabetes mellitus (T2DM)." | 6.52 | Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease. ( Bettencourt, N; Fontes-Carvalho, R; Gama, V; Ladeiras-Lopes, R; Leite-Moreira, A; Sampaio, F, 2015) |
| "Metformin is a first-line drug for the management of type 2 diabetes." | 5.43 | Metformin Protects H9C2 Cardiomyocytes from High-Glucose and Hypoxia/Reoxygenation Injury via Inhibition of Reactive Oxygen Species Generation and Inflammatory Responses: Role of AMPK and JNK. ( Chen, M; Hu, M; Liao, H; Yang, F; Ye, P, 2016) |
| "The present study tested the hypothesis that pretreatment with metformin decreases postprocedural myocardial injury and improves clinical outcomes in metabolic syndrome patients following percutaneous coronary intervention (PCI)." | 5.19 | Protective effect of metformin on myocardial injury in metabolic syndrome patients following percutaneous coronary intervention. ( Li, J; Song, SJ; Sun, XJ; Xu, JP; Xu, ZW; Zhao, XZ, 2014) |
| " The objective of this study was to evaluate the effect of metformin (DMBG) on autophagy during myocardial IRI with diabetes mellitus (DM)." | 4.31 | AMPK/mTOR-mediated therapeutic effect of metformin on myocardial ischaemia reperfusion injury in diabetic rat. ( Ge, J; Guan, L; Zhang, L; Zhang, X; Zhou, D, 2023) |
| "Numerous studies have demonstrated that metformin can reduce the incidence of myocardial infarction and improve the prognosis of patients." | 4.02 | Protective effects of metformin against myocardial ischemia‑reperfusion injury via AMPK‑dependent suppression of NOX4. ( Hou, SA; Shi, Y, 2021) |
| "Although both vildagliptin and metformin improved insulin resistance and attenuate myocardial injury caused by I/R, combined drugs provided better outcomes than single therapy by reducing arrhythmia score and mortality rate." | 3.80 | Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats. ( Apaijai, N; Chattipakorn, N; Chattipakorn, S; Chinda, K; Palee, S, 2014) |
| " Two known AMPK activators (metformin and AICAR) were used to verify the hypothesis that a transitory activation of AMPK at reperfusion may exert cardioprotection, as reflected in a reduction in myocardial infarct size." | 3.76 | Transitory activation of AMPK at reperfusion protects the ischaemic-reperfused rat myocardium against infarction. ( Davidson, SM; Gonçalves, LM; Mocanu, MM; Paiva, MA; Providência, LA; Yellon, DM, 2010) |
| "Metformin is a widely used drug in the treatment of type 2 diabetes mellitus (T2DM)." | 2.52 | Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease. ( Bettencourt, N; Fontes-Carvalho, R; Gama, V; Ladeiras-Lopes, R; Leite-Moreira, A; Sampaio, F, 2015) |
| "In patients with type 2 diabetes mellitus, treatment with metformin is associated with a lower cardiovascular morbidity and mortality, compared with alternative glucose-lowering drugs." | 2.47 | The cardioprotective effects of metformin. ( de Boer, RA; El Messaoudi, S; Riksen, NP; Rongen, GA, 2011) |
| "Metformin has been demonstrated to be beneficial for the treatment of an impaired myocardium as a result of ischemia/reperfusion (I/R) injury, and miR-34a may be involved in this process." | 1.62 | Metformin attenuates ischemia/reperfusion-induced apoptosis of cardiac cells by downregulation of p53/microRNA-34a via activation of SIRT1. ( Hao, J; Jiang, L; Jin, S; Li, W; Shi, Y, 2021) |
| "Metformin is an anti-diabetic drug that protects cardiac mitochondria during acute ER stress." | 1.62 | Chronic metformin treatment decreases cardiac injury during ischemia-reperfusion by attenuating endoplasmic reticulum stress with improved mitochondrial function. ( Chen, Q; Hu, Y; Lesnefsky, EJ; Thompson, J, 2021) |
| "Metformin 200 mg/kg was given intravenously to the cardiac I/R group (n = 10/group), either during ischemia (D-MET) or at the onset of reperfusion (R-MET)." | 1.56 | Metformin preferentially provides neuroprotection following cardiac ischemia/reperfusion in non-diabetic rats. ( Apaijai, N; Arunsak, B; Benjanuwattra, J; Chattipakorn, N; Chattipakorn, SC; Chunchai, T; Jaiwongkam, T; Kerdphoo, S; Wongsuchai, S, 2020) |
| "Metformin was given via femoral vein at 15 min prior to cardiac ischemia." | 1.56 | Acute administration of metformin prior to cardiac ischemia/reperfusion injury protects brain injury. ( Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Higgins, LA; Leech, T; Maneechote, C; Palee, S, 2020) |
| "Metformin treatment during early reperfusion improved mitochondrial calcium retention capacity, indicating decreased permeability transition pore (MPTP) opening." | 1.51 | Mitochondrial Complex I Inhibition by Metformin Limits Reperfusion Injury. ( Chen, Q; Hu, Y; Lesnefsky, EJ; Li, J; Maceyka, MW; Mohsin, AA; Quan, N; Rousselle, T; Samidurai, A; Thompson, J, 2019) |
| "Metformin could activate both the AMPKα1- and α2- mediated pathways, thus restoring autophagy flux during reperfusion." | 1.51 | Metformin promotes autophagy in ischemia/reperfusion myocardium via cytoplasmic AMPKα1 and nuclear AMPKα2 pathways. ( Ma, H; Mu, N; Wang, Y; Yang, Z; Yin, Y; Yu, L; Zheng, G, 2019) |
| "In metformin treated ischemic cells the DNA fragmentation and comet length were significantly reduced (p=." | 1.46 | Postconditioning with metformin attenuates apoptotic events in cardiomyoblasts associated with ischemic reperfusion injury. ( Ramachandran, R; Saraswathi, M, 2017) |
| "Metformin is a first-line drug for the management of type 2 diabetes." | 1.43 | Metformin Protects H9C2 Cardiomyocytes from High-Glucose and Hypoxia/Reoxygenation Injury via Inhibition of Reactive Oxygen Species Generation and Inflammatory Responses: Role of AMPK and JNK. ( Chen, M; Hu, M; Liao, H; Yang, F; Ye, P, 2016) |
| "Metformin was administered i." | 1.37 | The effect of metformin on the myocardial tolerance to ischemia-reperfusion injury in the rat model of diabetes mellitus type II. ( Bairamov, A; Galagudza, M; Grineva, E; Kravchuk, E; Vlasov, T, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (5.41) | 29.6817 |
| 2010's | 20 (54.05) | 24.3611 |
| 2020's | 15 (40.54) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, L | 1 |
| Zhang, X | 1 |
| Guan, L | 1 |
| Zhou, D | 1 |
| Ge, J | 1 |
| Li, Z | 1 |
| Wang, H | 1 |
| Zoungrana, LI | 1 |
| James, A | 1 |
| Slotabec, L | 1 |
| Didik, S | 1 |
| Fatmi, MK | 1 |
| Krause-Hauch, M | 1 |
| Lesnefsky, EJ | 4 |
| Li, J | 5 |
| Jo, W | 1 |
| Kang, KK | 1 |
| Chae, S | 1 |
| Son, WC | 1 |
| Benjanuwattra, J | 1 |
| Apaijai, N | 3 |
| Chunchai, T | 1 |
| Kerdphoo, S | 1 |
| Jaiwongkam, T | 1 |
| Arunsak, B | 1 |
| Wongsuchai, S | 1 |
| Chattipakorn, N | 5 |
| Chattipakorn, SC | 4 |
| Leech, T | 2 |
| Palee, S | 4 |
| Higgins, LA | 1 |
| Maneechote, C | 1 |
| Higgins, L | 2 |
| Huang, KY | 1 |
| Que, JQ | 1 |
| Hu, ZS | 1 |
| Yu, YW | 1 |
| Zhou, YY | 1 |
| Wang, L | 1 |
| Xue, YJ | 1 |
| Ji, KT | 1 |
| Zhang, XM | 1 |
| Chen, Q | 3 |
| Zhang, J | 2 |
| Huang, L | 1 |
| Shi, X | 1 |
| Yang, L | 3 |
| Hua, F | 1 |
| Ma, J | 1 |
| Zhu, W | 1 |
| Liu, X | 1 |
| Xuan, R | 1 |
| Shen, Y | 2 |
| Liu, J | 2 |
| Lai, X | 1 |
| Yu, P | 1 |
| Rozier, R | 1 |
| Paul, R | 1 |
| Madji Hounoum, B | 1 |
| Villa, E | 1 |
| Mhaidly, R | 1 |
| Chiche, J | 1 |
| Verhoeyen, E | 1 |
| Marchetti, S | 1 |
| Vandenberghe, A | 1 |
| Raucoules, M | 1 |
| Carles, M | 1 |
| Ricci, JE | 1 |
| Moheimani, HR | 1 |
| Amiriani, T | 1 |
| Alizadeh, AM | 1 |
| Jand, Y | 1 |
| Shakiba, D | 1 |
| Ensan, PS | 1 |
| Jafarzadeh, F | 1 |
| Rajaei, M | 1 |
| Enayati, A | 1 |
| Pourabouk, M | 1 |
| Aliazadeh, S | 1 |
| Pourkhani, AH | 1 |
| Mazaheri, Z | 1 |
| Zeyghami, MA | 1 |
| Dehpour, A | 1 |
| Khori, V | 1 |
| Peng, CL | 1 |
| Jiang, N | 1 |
| Zhao, JF | 1 |
| Liu, K | 1 |
| Jiang, W | 1 |
| Cao, PG | 1 |
| Li, W | 2 |
| Jin, S | 1 |
| Hao, J | 1 |
| Shi, Y | 2 |
| Jiang, L | 1 |
| Thompson, J | 2 |
| Hu, Y | 2 |
| Hou, SA | 1 |
| Ramachandran, R | 1 |
| Saraswathi, M | 1 |
| Wang, X | 1 |
| Kang, L | 1 |
| Zhu, M | 1 |
| Zhang, Q | 1 |
| Qi, Z | 1 |
| Mohsin, AA | 1 |
| Quan, N | 1 |
| Rousselle, T | 1 |
| Maceyka, MW | 1 |
| Samidurai, A | 1 |
| Wang, Y | 1 |
| Yang, Z | 1 |
| Zheng, G | 1 |
| Yu, L | 1 |
| Yin, Y | 1 |
| Mu, N | 1 |
| Ma, H | 1 |
| Hendriks, T | 1 |
| Al Ali, L | 1 |
| Maagdenberg, CG | 1 |
| van Melle, JP | 1 |
| Hummel, YM | 1 |
| Oudkerk, M | 1 |
| van Veldhuisen, DJ | 1 |
| Nijveldt, R | 1 |
| van der Horst, ICC | 1 |
| Lipsic, E | 1 |
| van der Harst, P | 1 |
| Luo, T | 1 |
| Zeng, X | 1 |
| Yang, W | 1 |
| Zhang, Y | 1 |
| El Messaoudi, S | 2 |
| Rongen, GA | 3 |
| Riksen, NP | 3 |
| Calvert, JW | 1 |
| Xu, JP | 1 |
| Zhao, XZ | 1 |
| Sun, XJ | 1 |
| Xu, ZW | 1 |
| Song, SJ | 2 |
| Chinda, K | 1 |
| Chattipakorn, S | 1 |
| Ünlü, M | 1 |
| Balta, Ş | 1 |
| Arslan, Z | 1 |
| Öztürk, C | 1 |
| Çelik, T | 1 |
| Iyisoy, A | 1 |
| Ladeiras-Lopes, R | 1 |
| Fontes-Carvalho, R | 1 |
| Bettencourt, N | 1 |
| Sampaio, F | 1 |
| Gama, V | 1 |
| Leite-Moreira, A | 1 |
| Paneni, F | 1 |
| Costantino, S | 1 |
| Cosentino, F | 1 |
| Hu, M | 1 |
| Ye, P | 1 |
| Liao, H | 1 |
| Chen, M | 1 |
| Yang, F | 1 |
| Paiva, M | 2 |
| Davidson, SM | 3 |
| Hausenloy, DJ | 2 |
| Monteiro, P | 1 |
| Gonçalves, L | 1 |
| Providência, L | 1 |
| Smits, P | 1 |
| Mocanu, MM | 3 |
| Yellon, DM | 3 |
| Paiva, MA | 1 |
| Gonçalves, LM | 1 |
| Providência, LA | 1 |
| Kravchuk, E | 1 |
| Grineva, E | 1 |
| Bairamov, A | 1 |
| Galagudza, M | 1 |
| Vlasov, T | 1 |
| de Boer, RA | 1 |
| Barreto-Torres, G | 1 |
| Parodi-Rullán, R | 1 |
| Javadov, S | 1 |
| Bhamra, GS | 1 |
| Carr, RD | 1 |
| Wynne, AM | 1 |
5 reviews available for metformin and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
Effects of metformin on the heart with ischaemia-reperfusion injury: Evidence of its benefits from in vitro, in vivo and clinical reports.
Topics: Animals; Heart; Humans; Metformin; Myocardial Reperfusion Injury; Myocardium | 2019 |
Metformin therapy in diabetes: the role of cardioprotection.
Topics: Animals; Cardiotonic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathi | 2013 |
Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Re | 2015 |
[Metformin and left ventricular remodeling after acute myocardial infarction: molecular mechanisms and clinical implications].
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Myocardial Reperfu | 2015 |
The cardioprotective effects of metformin.
Topics: Animals; Cardiotonic Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Cardiomyo | 2011 |
2 trials available for metformin and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
Agreement of 2D transthoracic echocardiography with cardiovascular magnetic resonance imaging after ST-elevation myocardial infarction.
Topics: Cardiovascular Agents; Drug Administration Schedule; Echocardiography; Female; Heart Ventricles; Hum | 2019 |
Protective effect of metformin on myocardial injury in metabolic syndrome patients following percutaneous coronary intervention.
Topics: Adult; Aged; Biomarkers; Cardiotonic Agents; Creatine Kinase, MB Form; Humans; Metabolic Syndrome; M | 2014 |
30 other studies available for metformin and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
AMPK/mTOR-mediated therapeutic effect of metformin on myocardial ischaemia reperfusion injury in diabetic rat.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Diabetes Mellitus; Humans; Metformin; Myocardial | 2023 |
Administration of metformin rescues age-related vulnerability to ischemic insults through mitochondrial energy metabolism.
Topics: Animals; Calcium; Energy Metabolism; Female; Ischemia; Male; Metformin; Mice; Mice, Inbred C57BL; Mi | 2023 |
Metformin Alleviates Left Ventricular Diastolic Dysfunction in a Rat Myocardial Ischemia Reperfusion Injury Model.
Topics: Animals; Disease Models, Animal; Echocardiography; Gene Expression Profiling; Gene Expression Regula | 2020 |
Metformin preferentially provides neuroprotection following cardiac ischemia/reperfusion in non-diabetic rats.
Topics: Administration, Intravenous; Amyloid beta-Peptides; Animals; Apoptosis; Brain; Brain Ischemia; Dendr | 2020 |
Acute administration of metformin prior to cardiac ischemia/reperfusion injury protects brain injury.
Topics: Amyloid beta-Peptides; Animals; Brain Injuries; Cyclic AMP-Dependent Protein Kinases; Dendrites; Den | 2020 |
Acute metformin treatment provides cardioprotection via improved mitochondrial function in cardiac ischemia / reperfusion injury.
Topics: Animals; Apoptosis; Arrhythmias, Cardiac; Cardiotonic Agents; Heart Function Tests; Hypoglycemic Age | 2020 |
Metformin suppresses inflammation and apoptosis of myocardiocytes by inhibiting autophagy in a model of ischemia-reperfusion injury.
Topics: Animals; Apoptosis; Autophagy; Drug Evaluation, Preclinical; Hypoglycemic Agents; Inflammation; Male | 2020 |
Metformin and myocardial ischemia and reperfusion injury: Moving toward "prime time" human use?
Topics: Humans; Metformin; Myocardial Ischemia; Myocardial Reperfusion Injury; Reperfusion Injury | 2021 |
Metformin protects against myocardial ischemia-reperfusion injury and cell pyroptosis via AMPK/NLRP3 inflammasome pathway.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Cells, Cultured; Cytokines; Diseas | 2020 |
Pharmacological preconditioning protects from ischemia/reperfusion-induced apoptosis by modulating Bcl-xL expression through a ROS-dependent mechanism.
Topics: Animals; Apoptosis; bcl-X Protein; Cell Survival; Humans; Hypoglycemic Agents; Metformin; Myocardial | 2021 |
Preconditioning and anti-apoptotic effects of Metformin and Cyclosporine-A in an isolated bile duct-ligated rat heart.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Apoptosis Regulatory Proteins; Bile Ducts; Cardio | 2021 |
Metformin relieves H/R-induced cardiomyocyte injury through miR-19a/ACSL axis - possible therapeutic target for myocardial I/R injury.
Topics: Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Case-Control Studies; Cell Hypoxia; Cell Li | 2021 |
Metformin attenuates ischemia/reperfusion-induced apoptosis of cardiac cells by downregulation of p53/microRNA-34a via activation of SIRT1.
Topics: Adult; Aged; AMP-Activated Protein Kinases; Animals; Apoptosis; Creatine Kinase, MB Form; Down-Regul | 2021 |
Chronic metformin treatment decreases cardiac injury during ischemia-reperfusion by attenuating endoplasmic reticulum stress with improved mitochondrial function.
Topics: Age Factors; Animals; Electron Transport Complex I; Endoplasmic Reticulum Stress; Male; Metformin; M | 2021 |
Protective effects of metformin against myocardial ischemia‑reperfusion injury via AMPK‑dependent suppression of NOX4.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Cell Hypoxia; Cell Survival; Creatine Kinase, MB | 2021 |
Postconditioning with metformin attenuates apoptotic events in cardiomyoblasts associated with ischemic reperfusion injury.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Cell Line; Cell Survival; Comet Assay; DNA Fragme | 2017 |
Metformin attenuates myocardial ischemia-reperfusion injury via up-regulation of antioxidant enzymes.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Antioxidants; Apoptosi | 2017 |
Mitochondrial Complex I Inhibition by Metformin Limits Reperfusion Injury.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line; Cytoprotection; Dose-Response Relationship, Drug; | 2019 |
Metformin promotes autophagy in ischemia/reperfusion myocardium via cytoplasmic AMPKα1 and nuclear AMPKα2 pathways.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; CARD Signaling Adaptor Proteins; Cell Nucleus; Ce | 2019 |
Treatment with metformin prevents myocardial ischemia-reperfusion injury via STEAP4 signaling pathway.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Male; Membrane Proteins; Metformin; Myocardial | 2019 |
Treating percutaneous coronary intervention-related myocardial injury with metformin.
Topics: Cardiotonic Agents; Humans; Metabolic Syndrome; Metformin; Myocardial Reperfusion Injury | 2014 |
Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats.
Topics: Adamantane; Animals; Arrhythmias, Cardiac; Calcium; Cardiotonic Agents; Dipeptidyl-Peptidase IV Inhi | 2014 |
The effect of metformin on cardiac fibrosis via differentiation of cardiac fibroblasts.
Topics: Cardiotonic Agents; Humans; Metabolic Syndrome; Metformin; Myocardial Reperfusion Injury | 2015 |
Response to the paper by Ünlü et al. entitled 'The effect of metformin on cardiac fibrosis via differentiation of cardiac fibroblasts'.
Topics: Cardiotonic Agents; Humans; Metabolic Syndrome; Metformin; Myocardial Reperfusion Injury | 2015 |
Metformin Protects H9C2 Cardiomyocytes from High-Glucose and Hypoxia/Reoxygenation Injury via Inhibition of Reactive Oxygen Species Generation and Inflammatory Responses: Role of AMPK and JNK.
Topics: AMP-Activated Protein Kinases; Animals; Anisomycin; Cell Survival; Cytokines; Electron Transport; Gl | 2016 |
Metformin prevents myocardial reperfusion injury by activating the adenosine receptor.
Topics: Adenosine; Animals; Biological Transport; Hypoglycemic Agents; In Vitro Techniques; Male; Metformin; | 2009 |
Transitory activation of AMPK at reperfusion protects the ischaemic-reperfused rat myocardium against infarction.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Enzyme Activation; Heart; Hemody | 2010 |
The effect of metformin on the myocardial tolerance to ischemia-reperfusion injury in the rat model of diabetes mellitus type II.
Topics: Animals; Animals, Newborn; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Disease Mode | 2011 |
The role of PPARα in metformin-induced attenuation of mitochondrial dysfunction in acute cardiac ischemia/reperfusion in rats.
Topics: Animals; Electron Transport Complex I; Electron Transport Complex II; Hypoglycemic Agents; L-Lactate | 2012 |
Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening.
Topics: Animals; Chromones; Diabetes Mellitus; Disease Models, Animal; Dose-Response Relationship, Drug; Dru | 2008 |